Orthofix Medical Inc. filings document regulatory disclosures for a medical technology company focused on spinal implants, therapeutic solutions, limb reconstruction systems, biologics and enabling technologies. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary net sales, guidance-related exhibits and non-GAAP measures including constant currency, free cash flow, adjusted gross profit and adjusted margin.
The company’s proxy and governance filings cover director elections, executive compensation, equity award disclosures, auditor ratification and common-share voting matters. Other current reports document Spine leadership changes, annual meeting results and board committee appointments.
Orthofix Medical Inc. executive Patrick Fisher, President, Global Limb Recon, reported selling 1,536 shares of common stock in open-market transactions on March 4 and 5, 2026 at weighted average prices of $12.9163 and $12.5508 per share. According to the disclosure, these sales were made to satisfy tax withholding obligations under a pre-existing sell-to-cover requirement approved by a board committee and were executed without his discretionary choice. After these transactions, he held 50,633 shares and restricted stock units in total, including 41,134 previously reported restricted stock units.
Orthofix Medical Inc. executive Aviva McPherron, President of Global Operations & Quality, reported selling a total of 2,559 shares of common stock in open-market transactions on March 4 and 5, 2026.
According to the disclosure, these sales were executed to satisfy tax withholding obligations related to the settlement of restricted stock units under a pre-approved, mandatory sell-to-cover program established by the Board’s Compensation and Talent Development Committee, and were carried out without any discretionary trading decision by the reporting person. After these transactions, McPherron directly owns 67,853 shares of Orthofix common stock, which includes 54,692 previously reported restricted stock units.
Orthofix Medical Inc. President, Global Spine, Max Reinhardt reported selling 2,133 shares of common stock in open-market transactions on March 4 and March 5, 2026. The shares were sold solely to satisfy tax withholding obligations from restricted stock unit settlement under a pre-approved sell-to-cover mandate, with no discretion exercised by him. After these sales, he directly held 25,348 shares, including 19,417 restricted stock units.
Orthofix Medical Inc. chief legal officer Jorge Andres Cedron reported automatic sales of common stock to cover tax withholding on recently settled restricted stock units. A total of 2,775 shares were sold in open‑market transactions on March 4–5 under a pre-existing, committee‑mandated sell-to-cover requirement.
The shares were sold at weighted-average prices of $12.9163 and $12.5508 per share across multiple trades within specified ranges, with no discretion exercised by Cedron. Following these transactions, he beneficially owns 62,749 shares of Orthofix common stock, including 53,902 previously reported restricted stock units.
Orthofix Medical Inc. President & CEO Massimo Calafiore received equity compensation awards on March 3, 2026. He was granted employee stock options for 273,279 shares at an exercise price of $0.00 and 115,119 shares of common stock in the form of restricted stock units.
The restricted stock units and options each vest in three equal annual installments, with one-third of the covered shares vesting on the first, second, and third anniversaries of the grant date. Following these grants, Calafiore directly holds 332,356 shares of common stock, including previously reported restricted stock units, and 273,279 stock options.
Orthofix Medical Inc. executive Aviva McPherron, President of Global Operations & Quality, received equity awards on the form’s grant date. She was granted 54,656 stock options with an exercise right and 23,024 shares of common stock in the form of restricted stock units, both at a stated price of $0.00 per share.
The options and restricted stock units each vest in three equal one-third installments on the first, second, and third anniversaries of the grant date. After these awards, she directly holds 70,412 shares of common stock, which includes 37,557 previously reported restricted stock units and 1,066 shares acquired under Orthofix’s Stock Purchase Plan.
Orthofix Medical Inc. CFO Julie Andrews received new equity awards consisting of stock options and restricted stock units. On the grant date, she acquired employee stock options for 84,261 shares at an exercise price of $0.00 per share and 35,495 shares of common stock as a restricted stock unit award.
The footnotes state that the restricted stock units and options each vest in three equal annual installments, with one-third of the covered shares vesting on the first, second, and third anniversaries of the grant date. Following these grants, her directly held common stock, including previously reported restricted stock units, totaled 93,534 shares.
Orthofix Medical Inc. reported that Chief Legal Officer Jorge Andres Cedron received equity awards in the form of stock options and restricted stock units. On March 3, 2026, he was granted 54,656 employee stock options and 23,024 shares of common stock as a grant/award acquisition.
The restricted stock units vest in equal one-third installments on the first, second, and third anniversaries of the grant date. The options also vest and become exercisable in equal one-third installments on each of the first three anniversaries. Following the stock grant, he directly holds 65,524 shares of common stock, which includes 36,767 previously reported restricted stock units.
Orthofix Medical Inc. reported that executive Lucas Vitale, its CP&BOO, acquired new equity awards. On March 3, 2026, he received 45,546 employee stock options and a separate grant of 19,186 shares of common stock in the form of restricted stock units.
The restricted stock units vest in three equal installments, with one-third of the shares vesting on each of the first, second, and third anniversaries of the grant date. Following these grants, Vitale directly holds 167,030 shares of common stock, including previously reported restricted stock units and shares acquired under Orthofix’s Stock Purchase Plan.
Orthofix Medical Inc. executive Patrick Fisher, President, Global Limb Recon, reported equity awards on March 3, 2026. He received 50,101 employee stock options with an exercise right to buy Orthofix common shares and a grant of 21,105 shares of common stock as restricted stock units at no cash cost.
The restricted stock units vest in equal one-third installments on the first, second, and third anniversaries of the grant date, and the options vest on the same three-year schedule. Following these grants, Fisher directly owns 52,169 shares of common stock, which include previously reported restricted stock units and 948 shares acquired under Orthofix’s Stock Purchase Plan, and holds 50,101 stock options.